Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk forbronchopulmonary dysplasia

Citation
Gk. Gupta et al., Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk forbronchopulmonary dysplasia, PEDIAT PULM, 30(4), 2000, pp. 275-281
Citations number
30
Categorie Soggetti
Pediatrics
Journal title
PEDIATRIC PULMONOLOGY
ISSN journal
87556863 → ACNP
Volume
30
Issue
4
Year of publication
2000
Pages
275 - 281
Database
ISI
SICI code
8755-6863(200010)30:4<275:EOEIBT>2.0.ZU;2-6
Abstract
We tested the hypothesis that inhaled beclomethasone therapy for prevention of bronchopulmonary dysplasia (BPD) reduces pulmonary inflammation. As par t of a randomized, placebo-controlled trial, interleukin-8 (IL-8) and inter leukin-l receptor antagonist (IL-1ra) concentrations in tracheal aspirates were measured as markers of pulmonary inflammation. On study days 1 (baseli ne), 8, 15, and day 28 of age, samples were obtained from enrolled infants (birth weights <1,251 g, gestational age <33 week, 3 to 14 days of age) who remained ventilated and had not received systemic glucocorticoid therapy. Cytokine levels (pg/mu g of free secretory component of immunoglobulin A) w ere compared between groups. We determined whether baseline cytokine levels modified treatment effect regarding subsequent need for systemic glucocort icoid therapy or occurrence of BPD (age 28 days). Tracheal aspirates were obtained from 161 infants (77 receiving beclomethas one, 84 receiving placebo). Median IL-8 levels were lower in beclomethasone versus placebo infants on study days 8 (82.9 vs. 209.2, P < 0.01) and 15 ( 37.4 vs. 77.4, P < 0.03) after controlling for antenatal glucocorticoid the rapy and maternal race. Median IL-1ra levels were lower in beclomethasone v ersus placebo infants only on study day 8 (86.5 vs. 153.3, P< 0.01). Fewer beclomethasone infants with baseline IL-8 levels in the interquartile range required systemic glucocorticoid therapy (beclomethasone 30.6% vs. placebo 65.8%, P < 0.01) or developed BPD (beclomethasone 42.4% vs, placebo 69.4%, P < 0.03). We conclude that early-inhaled beclomethasone therapy was associated with a reduction in pulmonary inflammation after 1 week of therapy. Beclomethason e-treated infants with moderately elevated baseline IL-8 levels received le ss subsequent systemic glucocorticoid therapy and had a lower incidence of BPD than nontreated infants. Pediatr Pulmonol. 2000; 30:275-281, (C) 2000 W iley-Liss, Inc.